Ph.D., Chief Scientific Officer, Foundation Medicine
Biography
Dr. Hegde oversees clinical product development, cancer genomics, and early-stage research, as well as regulatory and quality assurance, to accelerate advancement of the Company’s leading comprehensive genomic profiling portfolio. She is passionate about innovation in cancer research and translating innovations to precision medicine tools to advance care for patients. Dr. Hegde has spent nearly two decades in the biopharmaceutical industry, with a proven track record in drug development, registration, and commercialization of therapeutics with companion diagnostics in cancer immunotherapy. Prior to joining Foundation Medicine, Dr. Hegde spent 12 years at Genentech. Dr. Hegde served as senior director and principal scientist in oncology biomarker development at Genentech, during which she established and led the biomarker group accountable for translational science strategies in cancer immunotherapy. Dr. Hegde was instrumental in the approvals for atezolizumab in both the United States and European Union, as well as its forthcoming diagnostic filings.
Session Abstract – PMWC 2023 Silicon Valley
Track 4 - January 26 9.00 A.M.-4.30 P.M.
Track Chair: Cindy Perettie, Roche
- PMWC 2023 Award Ceremony
- Luis Alberto Diaz Jr., MSK
- Razelle Kurzrock, Medical College of Wisconsin - Non-invasive Liquid Biopsy Techniques (PANEL)
Chair: Razelle Kurzrock, Medical College of Wisconsin
- Apostolia Tsimberidou, MD Anderson
- Mandana Kamgar, MD Medical College of Wisconsin
- Mina Nikanjam, UCSD
- Ash Alizadeh, Stanford University - Liquid Biopsy Challenges and Limitations (PANEL)
Chair: Victor Lin, Mary Bird Perkins
- Luis Alberto Diaz Jr., MSK
- Maximilian Diehn, Stanford
- Dana Dilbeck, Agilent
- Emma Shtivelman, Cancer Commons - Liquid Biopsy in Clinical Trials: Learnings and COVID Experience (PANEL)
Chair: Cindy Perettie, Roche Diagnostics
- Eric Peters, Genenetch
- Andrew Mckenzie, Sarah Cannon
- Yang Pan, Gilead
- Alan Sandler, Mirati Therapeutics - Multi-Cancer Early Detection Through Multi-Biomarker Class Liquid Biopsy Testing
Chair: Tom Beer, Exact Sceinces
- Liquid Biopsy for Early Cancer Detection (PANEL)
Chair: Priti Hegde, Foundation Medicine
- Daniel Kim, UCSC
- Mike Nolan, Freenome
- Jeffrey Venstrom, Grail Bio
- Kathryn Phillips, UCSF
- Lon Castle, eviCore healthcare
- Tom Beer, Exact Sciences - Liquid Biopsy for Minimal Residual Disease (PANEL)
Chair: Minetta Liu, Natera
- Peter Bach, Delfi diagnostics
- Laura Vantveer, UCSF
- Susan Bobulsky, Adaptive
- Joshua Cohen, Johns Hopkins
- PMWC Showcase
- Harmeet Dhani, Biological Dynamics
- Varsha Rao, Claret Bio - PMWC NCI Showcase
- Xianghong Jasmine Zhou, EarlyDiagnostics
